We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

68 hedge funds and large institutions have $119M invested in Cartesian Therapeutics in 2024 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 9

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

8% more capital invested

Capital invested by funds: $110M → $119M (+$9.13M)

6% more funds holding

Funds holding: 64 → 68 (+4)

2.84% less ownership

Funds ownership: 28.75% → 25.91% (-2.8%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
68
Holders Change
+4
Holders Change %
+6.25%
% of All Funds
0.9%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
15
Increased
30
Reduced
9
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.78M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.77M
3
MB
MPM BioImpact
Massachusetts
+$1.86M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.73M
5
6CM
683 Capital Management
New York
+$1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.68M
2
GPP
Great Point Partners
Connecticut
-$3.22M
3
YU
Yale University
Connecticut
-$1.61M
4
AC
Armistice Capital
New York
-$1.59M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$43.4M -$8.68M -428,617 -15%
MB
2
MPM BioImpact
Massachusetts
$12.9M +$1.86M +91,716 +15%
BlackRock
3
BlackRock
New York
$11.8M +$4.78M +235,936 +56%
SL
4
Siren LLC
Connecticut
$10.2M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$7.69M +$3.77M +186,391 +77%
Citadel Advisors
6
Citadel Advisors
Florida
$5.64M -$1.23M -60,767 -16%
JP Morgan Chase
7
JP Morgan Chase
New York
$4.92M -$694K -34,278 -11%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$3.96M +$1.73M +85,557 +63%
EAM
9
Erste Asset Management
Austria
$3.26M – – –
State Street
10
State Street
Massachusetts
$3.09M +$306K +15,125 +10%
6CM
11
683 Capital Management
New York
$2.24M +$1M +49,569 +66%
Northern Trust
12
Northern Trust
Illinois
$1.7M +$646K +31,915 +51%
N
13
Nuveen
North Carolina
$1.29M +$970K +47,889 +198%
IC
14
Ikarian Capital
Texas
$934K -$547 -27 -0.1%
Goldman Sachs
15
Goldman Sachs
New York
$493K +$328K +16,189 +143%
Charles Schwab
16
Charles Schwab
California
$480K +$157K +7,755 +41%
FCH
17
Freestone Capital Holdings
Washington
$464K – – –
Morgan Stanley
18
Morgan Stanley
New York
$435K +$45.6K +2,251 +10%
DFG
19
Delphi Financial Group
Delaware
$395K – – –
AA
20
ALPS Advisors
Colorado
$368K +$416K +20,550 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$348K +$87.2K +4,305 +29%
Barclays
22
Barclays
United Kingdom
$342K +$152K +7,488 +64%
UBS Group
23
UBS Group
Switzerland
$315K +$248K +12,241 +229%
BFM
24
Boothbay Fund Management
New York
$260K -$547 -27 -0.2%
Renaissance Technologies
25
Renaissance Technologies
New York
$247K +$279K +13,800 New
1
2 3 4

RNAC Hedge Fund Activity: Q4 2024 in Review

68 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2024, worth a combined $119M — up 8.3% from $110M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new RNAC positions and 11 closed out — a net gain of 4 holders — while 30 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $4.78M. The largest seller was Fidelity Investments, cutting an estimated $8.68M.

  • 68 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2024, up from 64 in Q3 2024.
  • Funds reported $119M of Cartesian Therapeutics stock for Q4 2024, up 8.3% quarter-over-quarter.
  • 15 funds opened new Cartesian Therapeutics positions in Q4 2024 and 11 closed out, a net change of +4 holders.
  • The largest Cartesian Therapeutics buyer in Q4 2024 was BlackRock, an estimated $4.78M added.
  • The largest Cartesian Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $8.68M sold.

Based on aggregated 13F filings for Q4 2024.